$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000143853320000031 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$50.98M	$51.14M	$48.43M
YoY Change	9.2%	15.25%	8.33%
Cost Of Revenue	$2.070M	$1.189M	$1.494M
YoY Change	19.65%	-21.41%	52.6%
Gross Profit	$48.91M	$49.95M	$46.94M
YoY Change	8.79%	16.54%	7.34%
Gross Profit Margin	95.93%	97.67%	96.92%
Selling, General & Admin	$30.08M	$31.95M	$34.97M
YoY Change	32.45%	7.29%	-10.26%
% of Gross Profit	61.5%	63.97%	74.51%
Research & Development	$38.09M	$32.35M	$30.79M
YoY Change	5.6%	-2.62%	-18.83%
% of Gross Profit	77.88%	64.76%	65.6%
Depreciation & Amortization	$6.630M	$6.440M	$5.850M
YoY Change	25.33%	19.7%	20.87%
% of Gross Profit	13.56%	12.89%	12.46%
Operating Expenses	$74.12M	$64.30M	$65.76M
YoY Change	15.99%	-18.41%	-19.05%
Operating Profit	-$118.6M	-$19.44M	-$23.11M
YoY Change	320.88%	-43.56%	-36.73%
Interest Expense	-$380.0K	-$4.767M	-$4.634M
YoY Change	-96.74%	4.84%	-3.8%
% of Operating Profit
Other Income/Expense, Net	-$3.543M	-$3.091M	-$2.892M
YoY Change	71.99%	19.99%	37.52%
Pretax Income	-$122.1M	-$22.53M	-$26.00M
YoY Change	303.92%	-39.14%	-32.69%
Income Tax	-$471.0K	$23.00K	$65.00K
% Of Pretax Income
Net Earnings	-$121.6M	-$22.55M	-$26.07M
YoY Change	301.94%	-38.2%	-32.64%
Net Earnings / Revenue	-238.55%	-44.09%	-53.83%
Basic Earnings Per Share		-$0.44	-$0.58
Diluted Earnings Per Share	-$2.371M	-$0.44	-$0.58
COMMON SHARES
Basic Shares Outstanding	51.05M shares	50.93M shares	44.76M shares
Diluted Shares Outstanding		50.93M shares	44.76M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$356.6M	$399.3M	$370.3M
YoY Change	31.13%	34.84%	24.1%
Cash & Equivalents	$84.77M	$200.5M	$237.2M
Short-Term Investments	$271.8M	$198.8M	$133.1M
Other Short-Term Assets	$8.100M	$5.500M	$7.700M
YoY Change	26.56%	-48.11%	-27.36%
Inventory	$7.608M	$7.259M	$6.286M
Prepaid Expenses
Receivables	$15.93M	$15.00M	$14.10M
Other Receivables	$17.20M	$13.60M	$20.10M
Total Short-Term Assets	$410.4M	$497.7M	$505.6M
YoY Change	-4.35%	13.18%	10.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.418M	$5.696M	$2.930M
YoY Change	225.77%	95.74%	-2.82%
Goodwill	$900.0K	$936.0K	$936.0K
YoY Change	-3.85%	0.0%	0.0%
Intangibles	$154.1M
YoY Change	-1.96%
Long-Term Investments
YoY Change
Other Assets	$7.814M	$33.69M	$13.90M
YoY Change	-46.88%	170.53%	9.39%
Total Long-Term Assets	$197.0M	$194.5M	$173.1M
YoY Change	12.12%	11.74%	-9.15%
TOTAL ASSETS
Total Short-Term Assets	$410.4M	$497.7M	$505.6M
Total Long-Term Assets	$197.0M	$194.5M	$173.1M
Total Assets	$607.4M	$692.2M	$678.7M
YoY Change	0.44%	12.77%	4.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.13M	$9.431M	$10.20M
YoY Change	-54.41%	-31.82%	-18.54%
Accrued Expenses	$56.79M	$50.32M	$44.38M
YoY Change	9.76%	5.11%	-12.22%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$92.66M	$75.43M	$69.93M
YoY Change	-2.92%	-14.31%	-22.8%
LONG-TERM LIABILITIES
Long-Term Debt	$215.3M	$212.7M	$210.0M
YoY Change	5.08%	5.09%	5.05%
Other Long-Term Liabilities	$12.19M	$40.33M	$19.51M
YoY Change	-41.65%	87.69%	-11.74%
Total Long-Term Liabilities	$12.19M	$40.33M	$19.51M
YoY Change	-41.65%	87.69%	-11.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.66M	$75.43M	$69.93M
Total Long-Term Liabilities	$12.19M	$40.33M	$19.51M
Total Liabilities	$396.2M	$390.8M	$360.0M
YoY Change	3.29%	6.24%	-2.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$585.9M	-$464.3M	-$441.7M
YoY Change	40.69%	20.22%	26.31%
Common Stock	$798.0M	$765.3M	$759.0M
YoY Change	25.29%	21.29%	21.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$211.2M	$301.4M	$318.6M
YoY Change
Total Liabilities & Shareholders Equity	$607.4M	$692.2M	$678.7M
YoY Change	0.44%	12.77%	4.81%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$121.6M	-$22.55M	-$26.07M
YoY Change	301.94%	-38.2%	-32.64%
Depreciation, Depletion And Amortization	$6.630M	$6.440M	$5.850M
YoY Change	25.33%	19.7%	20.87%
Cash From Operating Activities	-$13.87M	$6.740M	-$6.450M
YoY Change	208.91%	-147.73%	-66.25%
INVESTING ACTIVITIES
Capital Expenditures	-$8.600M	-$6.920M	-$4.440M
YoY Change	116.08%	63.98%	30.97%
Acquisitions
YoY Change
Other Investing Activities	-$116.9M	-$36.25M	$72.23M
YoY Change	-2202.7%	-517.63%	152.38%
Cash From Investing Activities	-$125.5M	-$43.17M	$67.80M
YoY Change	-8043.67%	-1067.94%	168.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$108.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.04M	-350.0K	108.8M
YoY Change	27722.22%	-52.7%	-34096.87%
NET CHANGE
Cash From Operating Activities	-13.87M	6.740M	-6.450M
Cash From Investing Activities	-125.5M	-43.17M	67.80M
Cash From Financing Activities	25.04M	-350.0K	108.8M
Net Change In Cash	-114.3M	-36.78M	170.1M
YoY Change	3954.61%	253.65%	2833.45%
FREE CASH FLOW
Cash From Operating Activities	-$13.87M	$6.740M	-$6.450M
Capital Expenditures	-$8.600M	-$6.920M	-$4.440M
Free Cash Flow	-$5.270M	$13.66M	-$2.010M
YoY Change	933.33%	-237.98%	-87.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2020Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	RTRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51051820	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	200481000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62436000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	254655000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	335206000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255786000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15025000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18048000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	7259000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5516000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5015000	USD
CY2020Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	13615000	USD
CY2019Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1395000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	497682000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	429064000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5696000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2891000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33689000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14709000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	154217000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2020Q3	us-gaap	Assets Assets	692220000	USD
CY2019Q4	us-gaap	Assets Assets	604800000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9431000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26614000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50320000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6775000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8590000	USD
CY2020Q3	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8900000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8500000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	75426000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95449000	USD
CY2020Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	212651000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	204861000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40330000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20894000	USD
CY2020Q3	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	62400000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	62400000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	390807000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	383604000	USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51023187	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51023187	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43088921	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43088921	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	765307000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	636910000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-464253000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-416444000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	354000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	726000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	301413000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	692220000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	604800000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51139000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44373000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147338000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128651000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1189000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1513000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4054000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3509000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32349000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33220000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93387000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	104597000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31951000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29779000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	100061000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101418000	USD
CY2020Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5085000	USD
CY2019Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-702000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	7448000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5820000	USD
CY2020Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2020Q3	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019Q3	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
CY2020Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	70574000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	78810000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	204950000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	237844000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19435000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34437000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57612000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-109193000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	553000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-496000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	788000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-673000	USD
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1123000	USD
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2467000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4414000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7875000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4767000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4547000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14287000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14230000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3091000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2576000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9085000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7028000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22526000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37013000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66697000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116221000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-523000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18888000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50929575	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42943828	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46289103	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42109618	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-564000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	315000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-620000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	342000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-480000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	75000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	250000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2359000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23593000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36100000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48179000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113467000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17946000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15118000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1285000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1134000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-530000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	779000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7789000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7397000	USD
	rtrx	Provision Benefit For Inventory ProvisionBenefitForInventory	1317000	USD
	rtrx	Provision Benefit For Inventory ProvisionBenefitForInventory	972000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16612000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16101000	USD
	rtrx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	650000	USD
	rtrx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	507000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	7448000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-12180000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-10268000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4329000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25500000	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-117000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-539000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-446000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-15000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3195000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3989000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3813000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	671000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	12220000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	20181000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9629000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10213000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4962000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	18296000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6778000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28873000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53722000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2926000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	286000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13039000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11299000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	223152000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	180818000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	143003000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	150950000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64184000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18283000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6886000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2562000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1575000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1559000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1345000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	944000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108692000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1098000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1005000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	102674000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2172000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-74000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	138045000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37685000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200481000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65188000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255800000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5139000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4178000	USD
CY2020Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	914000	USD
CY2019Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	627000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-479000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	76000	USD
CY2020Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-566000	USD
CY2019Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	315000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	261000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	162000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	301413000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245957000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	1345000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	944000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16613000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16125000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108692000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	250000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2359000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-622000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	342000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1748000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1512000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	301413000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245957000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the three and nine months ended September 30, 2020, these governmental actions and the widespread economic disruption arising from the pandemic have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Focal segmental glomerulosclerosis ("FSGS")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Immunoglobulin A nephropathy ("IgAN")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal® has been recognized as the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades but is not currently labeled for this indication. In January 2020, we randomized the first patients in a Phase 3 clinical trial to evaluate the effects of Chenodal in adult and pediatric patients with CTX. The pivotal study, known as the RESTORE study, is intended to support a new drug application (“NDA”) submission for marketing authorization of Chenodal for CTX in the United States.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cooperative Research and Development Agreements ("CRADAs"):</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in two CRADAs, which form a multi-stakeholder approach to pool resources with leading experts, and incorporates the patient perspective early in the identification and development process. Retrophin has partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, NGLY1.org and Alagille Syndrome Alliance ("ALGSA"), aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for CTX patients for more than three decades.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam® (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15000000.0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51139000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44373000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147338000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128651000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	223300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	143000000.0	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255786000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	198170000	USD
CY2020Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	621000	USD
CY2020Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	6000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	198785000	USD
CY2020Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	56485000	USD
CY2020Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	523000	USD
CY2020Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	7000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	57001000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	254655000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1144000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255786000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	208906000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	598000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	209494000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	126300000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	351000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	57000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	126594000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	335206000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	949000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	67000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	101240000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	13000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	101240000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	13000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	79151000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	65000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	7509000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	86660000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	67000	USD
CY2020Q3	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000.0	USD
CY2020Q2	rtrx	Lessee Operating Lease Remeasurement Adjustment To Rou Asset And Lease Liability LesseeOperatingLeaseRemeasurementAdjustmentToROUAssetAndLeaseLiability	7500000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	603000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6200000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2412000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6020000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6386000	USD
CY2020Q3	rtrx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	25113000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46734000	USD
CY2020Q3	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	6884000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11130000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	28720000	USD
CY2020Q3	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1147000	USD
CY2020Q3	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	1266000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26307000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26300000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	28720000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27922000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	USD
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2020Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	230900000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200481000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	255786000	USD
CY2020Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	456267000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	71300000	USD
CY2020Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	71300000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	398524000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	70900000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	70900000	USD
CY2020Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5100000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	7400000	USD
CY2019Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-700000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5800000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	154200000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	259537000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	245802000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105320000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	88602000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	154217000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6023000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5007000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16482000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14594000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2020Q3	rtrx	Government Rebates Payable GovernmentRebatesPayable	11139000	USD
CY2019Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	6584000	USD
CY2020Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13393000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14045000	USD
CY2020Q3	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7857000	USD
CY2019Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7272000	USD
CY2020Q3	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6801000	USD
CY2019Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16067000	USD
CY2020Q3	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	7941000	USD
CY2019Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3552000	USD
CY2020Q3	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3189000	USD
CY2019Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4225000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50320000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50929575	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-22549000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42943828	shares
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46289103	shares
	us-gaap	Net Income Loss NetIncomeLoss	-47809000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42109618	shares
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16911846000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15449154000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16849452000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16218443000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5400000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.34
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5398000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4340000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17262000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16608000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18900000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18000000.0	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2020Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2858000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2713000	USD
CY2020Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4401000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3369000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	7259000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3800000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15000000.0	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7500000	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	15.50
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108700000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000000.0	USD

Files In Submission

Name	View Source	Status
0001438533-20-000031-index-headers.html	Edgar Link	pending
0001438533-20-000031-index.html	Edgar Link	pending
0001438533-20-000031.txt	Edgar Link	pending
0001438533-20-000031-xbrl.zip	Edgar Link	pending
ex09302020311.htm	Edgar Link	pending
ex09302020312.htm	Edgar Link	pending
ex09302020321.htm	Edgar Link	pending
ex09302020322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20200930.htm	Edgar Link	pending
rtrx-20200930.xsd	Edgar Link	pending
rtrx-20200930xex101.htm	Edgar Link	pending
rtrx-20200930_cal.xml	Edgar Link	unprocessable
rtrx-20200930_def.xml	Edgar Link	unprocessable
rtrx-20200930_g1.jpg	Edgar Link	pending
rtrx-20200930_htm.xml	Edgar Link	completed
rtrx-20200930_lab.xml	Edgar Link	unprocessable
rtrx-20200930_pre.xml	Edgar Link	unprocessable
rtrx20200930ex102.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2020 Q4 Form 10-Q Financial Statement

#000143853320000031 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2020 Q4 Form 10-Q Financial Statement

#000143853320000031 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx